LSTA

0.87344.02%
GB

Gregory Bailey Brown

Independent Chairman of the Board

Dr. Gregory Bailey Brown, M.D., MBA., also known as Greg, was Director of Memgen, Inc. Dr. Brown is an Independent Chairman of the Board of Aquestive Therapeutics, Inc. from 2024. He co-founded HealthCare Royalty Partners (HCR Partners) in January 2007 and has been its Managing Director since October 2007. He serves as Member of Advisory Board at FemHealth Ventures LLC. He serves as Chief Financial officer at Memgen, Inc. and serves as Chief Executive Officer from February 2020. He serves as Director at PharmacoPhotonics, Inc. since June 2020. Dr. Brown serves Chairman of the Strategic Advisory Board at HealthCare Royalty Partners since 2016 and was its Vice Chairman until December 2022. Dr. Brown is a Co-Founder of HealthCare Royalty Partners, L.P. and serves as its Managing Director. He is the Director of Memgen since March 2020. He has previously served as a Founding Managing Director at the HealthCare Royalty Partners. In addition, Dr. Brown leads the European business development efforts and manages various operational functions. Dr. Brown was a General Partner at Paul Capital Partners from 2002 to 2007, where he was responsible for global sourcing and co-managing the firm's royalty investment and being primarily responsible for the execution and management. He was General Partner at Paul Royalty Fund III, L.P. and Paul Royalty Fund II, L.P. He joined Paul Royalty in 2003. Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners where he co-managed that firm's royalty investments as a member of the royalty management committee. Dr. Brown shared leadership of the Royalty Fund Team and also focused on the identification, evaluation and pursuit of new business opportunities. He was the Co-Head of the Investment Banking Department as well as Managing Director of Healthcare Investment Banking at Canaccord Genuity Inc. (formerly, Adams, Harkness & Hill) from 1997 to 2002. He served as Vice President of Corporate Finance at Vector Securities International. Dr. Brown served as Biotech Analyst at Vector Securities International, LLC from 1992 to 1997 both as a Healthcare Investment Banker and a Wall Street Journal All-Star Biotechnology Research Analyst. Prior to his career in investments, Dr. Brown was a Thoracic and Vascular Surgeon and is educated as a transplantation immunologist. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. He is a practicing thoracic and vascular surgeon and founded HMO. He has been the Chairman of Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences, Inc.) since February 16, 2017 and has been its Director since October 12, 2016. He served as Chairman of Invuity, Inc. from October 2014 to December 31, 2015. He serves as a Director of Nuron Biotech and Acufocus, Inc. He has been a Director of Aquestive Therapeutics, Inc. since March 2007. He serves as a Board Member of the Biomedical Science Careers Program. Dr. Brown served as a Director of Oscient Pharmaceuticals Corp. since August 2006. He served as a Director of Forticell Bioscience, Inc. from March 2003 to June 20, 2006. Dr. Brown is also a Senior Advisor to Back Bay Health Care Capital, a venture capital firm with a focus in European life sciences. He serves as a Director of Vanderbilt Clinical S.a.r.l. He was the Director at Cambrex Corporation from October 31, 2017 until December 4, 2019. He has been an Independent Non-Executive Director at Faron Pharmaceuticals Oy since May 16, 2017. He is a board observer at Cardiorentis AG, Vanderbilt S.a.r.l. and TearScience. He served as a Director of Invuity, Inc. from February 2014 to December 31, 2015. He served as Director of AcuFocus, Inc. He was an Observer on the Board of Acorda Therapeutics, Inc. He serves on the boards of FAST Biomedical since January 2020. He has expertise on the technical, clinical, scientific and medical evaluation of products in healthcare systems as well as the payor/reimbursement analysis and dynamics. Dr. Brown currently serves on the boards of Adimab, LLC. Dr. Brown received M.D. from SUNY Upstate Medical Center, an M.B.A. from Harvard Business School and a B.A. from Yale University.

Positions